Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Non Operating Income: 2021-2025

Historic Non Operating Income for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to $58.1 million.

  • SAB Biotherapeutics' Non Operating Income rose 5954.91% to $58.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.9 million, marking a year-over-year increase of 897.60%. This contributed to the annual value of $8.8 million for FY2024, which is 313.80% up from last year.
  • According to the latest figures from Q3 2025, SAB Biotherapeutics' Non Operating Income is $58.1 million, which was up 15,307.50% from -$382,209 recorded in Q2 2025.
  • SAB Biotherapeutics' Non Operating Income's 5-year high stood at $58.1 million during Q3 2025, with a 5-year trough of -$4.0 million in Q4 2023.
  • Moreover, its 3-year median value for Non Operating Income was $220,605 (2023), whereas its average is $6.2 million.
  • Its Non Operating Income has fluctuated over the past 5 years, first crashed by 36,168.02% in 2023, then surged by 13,108.14% in 2024.
  • Over the past 5 years, SAB Biotherapeutics' Non Operating Income (Quarterly) stood at -$450,448 in 2021, then surged by 102.45% to $11,043 in 2022, then plummeted by 36,168.02% to -$4.0 million in 2023, then surged by 65.21% to -$1.4 million in 2024, then skyrocketed by 5,954.91% to $58.1 million in 2025.
  • Its Non Operating Income was $58.1 million in Q3 2025, compared to -$382,209 in Q2 2025 and $5.6 million in Q1 2025.